Señales en vivo de ZEAL.CO | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 10:59):

Stats
Volumen de hoy	200 057
Volumen promedio	396 561
Capitalización de mercado	38.77B
EPS	DKK0 ( 2024-02-27 )
Próxima fecha de ganancias	( DKK-4.20 ) 2024-05-16
Last Dividend	DKK0 ( N/A )
Next Dividend	DKK0 ( N/A )
P/E	-50.00
ATR14	DKK0.763 (0.12%)

Volumen Correlación

Largo: 0.24 (neutral)

Corto: 0.87 (strong)

Signal:(59.293) Same movement expected

Zealand Pharma A/S Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Zealand Pharma A/S Correlación - Moneda/Commodity

-0.18
( neutral )

-0.11
( neutral )

0.08
( neutral )

0.07
( neutral )

-0.51
( weak negative )

0.23
( neutral )

Zealand Pharma A/S Finanzas

Annual	2023
Ingresos:	DKK342.79M
Beneficio Bruto:	DKK295.31M (86.15 %)
EPS:	DKK-12.44

FY	2023
Ingresos:	DKK342.79M
Beneficio Bruto:	DKK295.31M (86.15 %)
EPS:	DKK-12.44

FY	2022
Ingresos:	DKK103.99M
Beneficio Bruto:	DKK73.28M (70.47 %)
EPS:	DKK-20.90

FY	2021
Ingresos:	DKK292.57M
Beneficio Bruto:	DKK173.75M (59.39 %)
EPS:	DKK-23.75

Financial Reports:

No articles found.

Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.